Streetbeat News

Analyst Ratings

SMWB

Similarweb reported Q2 earnings per share (EPS) of $(0.04), beating the analyst consensus estimate of $(0.07) by 42.86%. However, the company's quarterly sales of $53.68M missed the estimate of $53.74M by 0.11%. The EPS is an 84.62% increase from the same period last year, and the sales represent a 12.81% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 9:38 pm

MBC

MasterBrand (NYSE:MBC) reported Q2 earnings of $0.42 per share, beating the analyst consensus estimate of $0.31 by 35.48%. However, the company's quarterly sales of $695.10 million missed the analyst consensus estimate of $710.00 million by 2.10%.

Portfolio Pulse from mahesh@benzinga.com

August 08, 2023 | 9:29 pm

OLMA

Olema Pharmaceuticals reported Q2 losses of $(0.49) per share, beating the analyst consensus estimate of $(0.73) by 32.88 percent. This represents a 40.24 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 9:19 pm

EFTR

eFFECTOR Therapeutics reported Q2 losses of $(0.17) per share, beating the analyst consensus estimate of $(0.20) by 15 percent. This is unchanged from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 9:11 pm

KIND

Nextdoor Holdings (NYSE:KIND) reported Q2 earnings per share (EPS) of $(0.09), beating the analyst consensus estimate of $(0.10) by 10%. The company also reported quarterly sales of $56.89M, surpassing the analyst consensus estimate of $53.50M by 6.33%. Both EPS and sales show an increase compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 08, 2023 | 9:08 pm

JANX

Janux Therapeutics reported Q2 earnings per share (EPS) of $(0.42), beating the analyst consensus estimate of $(0.52) by 19.23%. However, this is a 2.44% decrease from the same period last year. The company also reported quarterly sales of $1.06M, surpassing the analyst consensus estimate of $870.00K by 21.49%, but this is a 55.31% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 9:07 pm

VRDN

Viridian Therapeutics reported Q2 losses of $(1.27) per share, beating the analyst consensus estimate of $(1.29) by 1.55 percent. However, this is a 19.81 percent decrease over losses from the same period last year. The company's quarterly sales of $72.00 thousand missed the analyst consensus estimate of $220.00 thousand by 67.27 percent, marking a 71.88 percent decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 9:05 pm

QDEL

QuidelOrtho (NASDAQ:QDEL) reported Q2 earnings of $0.26 per share, beating the analyst consensus estimate of $0.25 by 4%. However, this is a 88.89% decrease from the same period last year. The company also reported quarterly sales of $665.10 million, beating the analyst consensus estimate of $619.84 million by 7.30%, marking an 8.43% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 9:00 pm

BOOT

Boot Barn Holdings (NYSE:BOOT) has received mostly bullish ratings from 20 analysts over the past quarter, with an average price target of $98.65, indicating a potential upside from the current price of $97.58. The average price target has increased by 5.95% from the previous average of $93.11.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 9:00 pm

STEP

Over the past 3 months, 6 analysts have published their opinion on StepStone Group (NASDAQ:STEP) stock, all of them being indifferent. The company has an average price target of $27.83, which has increased by 3.07% from the previous average price target of $27.00.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 9:00 pm